Iacopo Olivotto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8019781/publications.pdf

Version: 2024-02-01

337 papers	22,938 citations	13087 68 h-index	9854 141 g-index
367 all docs	367 docs citations	367 times ranked	12893 citing authors

#	Article	IF	Citations
1	Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2003, 348, 295-303.	13.9	1,217
2	Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction. Circulation, 2006, 114, 2232-2239.	1.6	830
3	Short-Term Clinical Outcome of Patients With Acute Pulmonary Embolism, Normal Blood Pressure, and Echocardiographic Right Ventricular Dysfunction. Circulation, 2000, 101, 2817-2822.	1.6	785
4	Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy. Circulation, 2014, 130, 484-495.	1.6	783
5	Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy. Circulation, 2001, 104, 2517-2524.	1.6	731
6	Epidemiology of Hypertrophic Cardiomyopathyâ€“Related Death. Circulation, 2000, 102, 858-864.	1.6	727
7	Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2005, 46, 470-476.	1.2	677
8	Coronary Microvascular Dysfunction and Prognosis in Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2003, 349, 1027-1035.	13.9	670
9	Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2014, 64, 83-99.	1.2	541
10	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	6.3	481
11	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. Circulation, 2018, 138, 1387-1398.	1.6	468
12	Hypertrophic Cardiomyopathy Phenotype Revisited After 50 Years With Cardiovascular Magnetic Resonance. Journal of the American College of Cardiology, 2009, 54, 220-228.	1.2	399
13	Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy. Circulation, 2013, 127, 575-584.	1.6	347
14	Mitral Valve Abnormalities Identified by Cardiovascular Magnetic Resonance Represent a Primary Phenotypic Expression of Hypertrophic Cardiomyopathy. Circulation, 2011, 124, 40-47.	1.6	343
15	Gender-Related Differences in the Clinical Presentation and Outcome of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2005, 46, 480-487.	1.2	342
16	Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2002, 39, 301-307.	1.2	329
17	Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy. Mayo Clinic Proceedings, 2008, 83, 630-638.	1.4	296
18	Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). European Heart Journal, 2019, 40, 19-33.	1.0	288

#	Article	IF	Citations
19	Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2008, 52, 559-566.	1.2	269
20	Hypertrophic cardiomyopathy in tuscany: Clinical course and outcome in an unselected regional population. Journal of the American College of Cardiology, 1995, 26, 1529-1536.	1.2	265
21	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. Journal of Medical Genetics, 2017, 54, 288-296.	1.5	262
22	Patterns of Disease Progression in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2012, 5, 535-546.	1.6	258
23	Clinical Features and Outcome of Hypertrophic Cardiomyopathy Associated With Triple Sarcomere Protein Gene Mutations. Journal of the American College of Cardiology, 2010, 55, 1444-1453.	1.2	256
24	The Case for Myocardial Ischemia in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2009, 54, 866-875.	1.2	254
25	Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 1999, 33, 2044-2051.	1.2	230
26	Prognostic Significance of Left Atrial Size in Patients With Hypertrophic Cardiomyopathy (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.7	224
27	Relevance of Coronary Microvascular Flow Impairment to Long-Term Remodeling and Systolic Dysfunction in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2006, 47, 1043-1048.	1.2	208
28	Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy. Mayo Clinic Proceedings, 2008, 83, 630-638.	1.4	198
29	Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy. Circulation, 2020, 141, 828-842.	1.6	181
30	Mutation E169K in Junctophilin-2 Causes Atrial Fibrillation Due to Impaired RyR2 Stabilization. Journal of the American College of Cardiology, 2013, 62, 2010-2019.	1.2	165
31	Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry. Journal of the American College of Cardiology, 2019, 74, 2333-2345.	1.2	152
32	International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation, 2018, 137, 1015-1023.	1.6	149
33	Reevaluating the Genetic Contribution of Monogenic Dilated Cardiomyopathy. Circulation, 2020, 141, 387-398.	1.6	148
34	Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). JAMA Cardiology, 2019, 4, 918.	3.0	147
35	The coronary circulation and blood flow in left ventricular hypertrophy. Journal of Molecular and Cellular Cardiology, 2012, 52, 857-864.	0.9	144
36	Contemporary Natural History and Management of Nonobstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2016, 67, 1399-1409.	1.2	142

#	Article	IF	Citations
37	Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. European Heart Journal, 2012, 33, 1724-1733.	1.0	141
38	Spectrum and Clinical Significance of Systolic Function and Myocardial Fibrosis Assessed by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2010, 106, 261-267.	0.7	139
39	Microvascular Function Is Selectively Impaired in Patients With Hypertrophic Cardiomyopathy and Sarcomere Myofilament Gene Mutations. Journal of the American College of Cardiology, 2011, 58, 839-848.	1.2	138
40	Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2003, 41, 315-321.	1.2	134
41	Usefulness of Bedside Testing for Brain Natriuretic Peptide to Identify Right Ventricular Dysfunction and Outcome in Normotensive Patients With Acute Pulmonary Embolism. American Journal of Cardiology, 2006, 97, 1386-1390.	0.7	133
42	A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. Circulation, 2020, 142, 217-229.	1.6	129
43	Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace, 2010, 12, 347-355.	0.7	127
44	Surgical Myectomy Versus Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2007, 50, 831-834.	1.2	118
45	Obesity and its Association to Phenotype and Clinical Course in Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2013, 62, 449-457.	1.2	118
46	Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations. Journal of the American College of Cardiology, 2014, 64, 2589-2600.	1.2	118
47	Utility of an integrated clinical, echocardiographic, and venous ultrasonographic approach for triage of patients with suspected pulmonary embolism. American Journal of Cardiology, 1998, 82, 1230-1235.	0.7	109
48	Cardiac Involvement in Fabry Disease. Journal of the American College of Cardiology, 2021, 77, 922-936.	1.2	109
49	Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction. Circulation, 2020, 141, 1371-1383.	1.6	108
50	Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2016, 9, .	1.6	103
51	Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e004124.	1.6	103
52	Association of Persistent Right Ventricular Dysfunction at Hospital Discharge After Acute Pulmonary Embolism With Recurrent Thromboembolic Events. Archives of Internal Medicine, 2006, 166, 2151.	4.3	101
53	Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. European Journal of Heart Failure, 2016, 18, 1106-1118.	2.9	101
54	Multidimensional structure-function relationships in human Î²-cardiac myosin from population-scale genetic variation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6701-6706.	3.3	98

#	Article	IF	Citations
55	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2021, 397, 2467-2475.	6.3	98
56	Left Ventricular Apical Ballooning Syndrome as a Novel Cause of Acute Mitral Regurgitation. Journal of the American College of Cardiology, 2007, 50, 647-649.	1.2	97
57	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. European Journal of Heart Failure, 2020, 22, 1076-1096.	2.9	96
58	Left Atrial Remodeling in Hypertrophic Cardiomyopathy and Susceptibility Markers for Atrial Fibrillation Identified by Cardiovascular Magnetic Resonance. American Journal of Cardiology, 2014, 113, 1394-1400.	0.7	95
59	Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. American Journal of Cardiology, 2016, 117, 1651-1654.	0.7	95
60	The familial hypertrophic cardiomyopathyâ€associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. Journal of Physiology, 2008, 586, 3639-3644.	1.3	90
61	Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. Genome Medicine, 2019, 11, 5.	3.6	90
62	Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. European Heart Journal, 2011, 32, 1114-1120.	1.0	88
63	Usefulness and Safety of Transcatheter Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2007, 99, 1575-1581.	0.7	85
64	Stress echo 2020: the international stress echo study in ischemic and non-ischemic heart disease. Cardiovascular Ultrasound, 2017, 15, 3.	0.5	82
65	Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events. JAMA Cardiology, 2018, 3, 520.	3.0	78
66	Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy. JAMA Cardiology, 2020, 5, 65.	3.0	78
67	Significance of Sarcomere Gene Mutations Analysis in the End-Stage Phase of Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2014, 114, 769-776.	0.7	76
68	Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2017, 10, .	1.6	76
69	Role of Genetic Testing in Inherited Cardiovascular Disease. JAMA Cardiology, 2017, 2, 1153.	3.0	75
70	Novel Î±-Actinin 2 Variant Associated With Familial Hypertrophic Cardiomyopathy and Juvenile Atrial Arrhythmias. Circulation: Cardiovascular Genetics, 2014, 7, 741-750.	5.1	74
71	The spectrum of myocarditis: from pathology to the clinics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 279-301.	1.4	73
72	Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. Nature Reviews Cardiology, 2009, 6, 317-321.	6.1	72

#	Article	IF	Citations
73	Î² Blockers for Prevention of Exercise-Induced Left Ventricular Outflow Tract Obstruction in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2012, 110, 715-719.	0.7	71
74	Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 1988-1996.	1.0	69
75	Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. American Heart Journal, 1998, 136, 972-981.	1.2	68
76	Spatial Relationship Between Coronary Microvascular Dysfunction and Delayed Contrast Enhancement in Patients with Hypertrophic Cardiomyopathy. Journal of Nuclear Medicine, 2008, 49, 1090-1096.	2.8	68
77	Role of Exercise Testing in HypertrophicÂCardiomyopathy. JACC: Cardiovascular Imaging, 2017, 10, 1374-1386.	2.3	68
78	Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2015, 8, 1014-1021.	1.6	67
79	Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. Cardiovascular Research, 2015, 105, 409-423.	1.8	66
80	The Many Faces of Hypertrophic Cardiomyopathy: From Developmental Biology to Clinical Practice. Journal of Cardiovascular Translational Research, 2009, 2, 349-367.	1.1	65
81	The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. Heart Rhythm, 2020, 17, 142-151.	0.3	65
82	A molecular screening strategy based on Î²-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. Journal of Cardiovascular Medicine, 2006, 7, 601-607.	0.6	64
83	Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovascular Ultrasound, 2010, 8, 7.	0.5	62
84	Significance of Late Gadolinium Enhancement at Right Ventricular Attachment to Ventricular Septum in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2015, 116, 436-441.	0.7	62
85	MR Imaging in Hypertrophic Cardiomyopathy: From Magnet to Bedside. Radiology, 2014, 273, 329-348.	3.6	60
86	Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. International Journal of Cardiology, 2020, 300, 191-195.	0.8	60
87	Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. JAMA Cardiology, 2020, 5, 83.	3.0	60
88	Metabolomic fingerprint of heart failure in humans: A nuclear magnetic resonance spectroscopy analysis. International Journal of Cardiology, 2013, 168, e113-e115.	0.8	59
89	Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2021, 78, 2518-2532.	1.2	59
90	Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study. European Journal of Internal Medicine, 2022, 97, 36-41.	1.0	58

#	Article	IF	Citations
91	Determinants of echocardiographic left atrial volume: implications for normalcy. European Journal of Echocardiography, 2011, 12, 826-833.	2.3	57
92	The Italian registry for hypertrophic cardiomyopathy: A nationwide survey. American Heart Journal, 2005, 150, 947-954.	1.2	56
93	Comparison of longâ€term outcome in anthracyclineâ€related versus idiopathic dilated cardiomyopathy: a single centre experience. European Journal of Heart Failure, 2018, 20, 898-906.	2.9	54
94	Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center. Genetics in Medicine, 2019, 21, 284-292.	1.1	54
95	Microvascular Dysfunction, Myocardial Ischemia, and Progression to Heart Failure in Patients with Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2009, 2, 452-461.	1.1	53
96	The electrocardiogram in the diagnosis and management of patients with dilated cardiomyopathy. European Journal of Heart Failure, 2020, 22, 1097-1107.	2.9	52
97	Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2016, 9, e002764.	1.6	51
98	Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models. Journal of the American Heart Association, 2017, 6, .	1.6	51
99	Signal-averaged P-wave duration and risk of paroxysmal atrial fibrillation in hyperthyroidism. American Journal of Cardiology, 1996, 77, 266-269.	0.7	50
100	Improving Survival Rates of Patients With Idiopathic Dilated Cardiomyopathy in Tuscany Over 3 Decades. Circulation: Heart Failure, 2013, 6, 913-921.	1.6	50
101	B-lines with Lung Ultrasound: The Optimal Scan Technique atÂRest and During Stress. Ultrasound in Medicine and Biology, 2017, 43, 2558-2566.	0.7	50
102	Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005820.	2.1	50
103	Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Andersonâ€“Fabry disease. European Journal of Heart Failure, 2013, 15, 1363-1373.	2.9	49
104	Late sodium current inhibitors to treat exerciseâ€induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium. British Journal of Pharmacology, 2018, 175, 2635-2652.	2.7	49
105	Research priorities in sarcomeric cardiomyopathies. Cardiovascular Research, 2015, 105, 449-456.	1.8	48
106	Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2017, 6, .	1.6	48
107	Contemporary genetic testing in inherited cardiac disease. Journal of Cardiovascular Medicine, 2018, 19, 1-11.	0.6	48
108	Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2020, 13, e007230.	1.6	48

#	Article	IF	Citations
109	Study Design and Rationale of EXPLORER-HCM. Circulation: Heart Failure, 2020, 13, e006853.	1.6	48
110	Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, 396-405.	1.6	47
111	Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy. Heart Rhythm, 2016, 13, 457-463.	0.3	46
112	Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e005191.	1.6	46
113	Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 118, 432-439.	0.7	45
114	Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: the importance of clinical context. European Heart Journal Cardiovascular Imaging, 2018, 19, 601-610.	0.5	45
115	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. Journal of the American College of Cardiology, 2020, 76, 186-197.	1.2	45
116	Systematic large-scale assessment of the genetic architecture of left ventricular noncompaction reveals diverse etiologies. Genetics in Medicine, 2021, 23, 856-864.	1.1	45
117	Determinants of treatment strategies and survival in acute myocardial infarction: a population-based study in the Florence district, Italy Results of the acute myocardial infarction Florence registry (AMI-Florence),,. European Heart Journal, 2003, 24, 1195-1203.	1.0	44
118	Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Molecular Genetics and Metabolism, 2020, 131, 219-228.	0.5	44
119	Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in tuscany. American Journal of Cardiology, 2003, 92, 1358-1362.	0.7	43
120	Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. Circulation, 2019, 139, 830-833.	1.6	43
121	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. European Heart Journal, 2021, 42, 3932-3944.	1.0	43
122	Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the <scp>ACâ€TIVE</scp> study, an <scp>Italian nationwide survey</scp>. European Journal of Heart Failure, 2022, 24, 1377-1386.	2.9	43
123	Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	42
124	Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing?. Journal of the American Heart Association, 2020, 9, e015473.	1.6	42
125	Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. European Journal of Heart Failure, 2005, 7, 566-571.	2.9	41
126	Hemodynamic Progression and Outcome of Asymptomatic Aortic Stenosis in Primary Care. American Journal of Cardiology, 2012, 109, 718-723.	0.7	41

#	Article	IF	Citations
127	Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy. Cardiovascular Research, 2020, 116, 1585-1599.	1.8	40
128	Timing and Significance of Exercise-Induced Left Ventricular Outflow Tract Pressure Gradients in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2010, 106, 1301-1306.	0.7	39
129	Dynamic assessment of 'valvular reserve capacity' in patients with rheumatic mitral stenosis. European Heart Journal Cardiovascular Imaging, 2012, 13, 476-482.	0.5	39
130	Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions. Genetics in Medicine, 2021, 23, 69-79.	1.1	39
131	Relationship of ECG findings to phenotypic expression in patients with hypertrophic cardiomyopathy: A cardiac magnetic resonance study. International Journal of Cardiology, 2013, 167, 1038-1045.	0.8	38
132	Prognostic role of stress echocardiography in hypertrophic cardiomyopathy: The International Stress Echo Registry. International Journal of Cardiology, 2016, 219, 331-338.	0.8	38
133	The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. Revista Portuguesa De Cardiologia, 2018, 37, 1-10.	0.2	38
134	Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003062.	1.6	38
135	Diagnosis and Management of Rare Cardiomyopathies in Adult and Paediatric Patients. A Position Paper of the Italian Society of Cardiology (SIC) and Italian Society of Paediatric Cardiology (SICP). International Journal of Cardiology, 2022, 357, 55-71.	0.8	36
136	Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy. JACC Basic To Translational Science, 2019, 4, 795-813.	1.9	35
137	Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy. JAMA Oncology, 2021, 7, 1544.	3.4	35
138	Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Outpatients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2013, 112, 1190-1196.	0.7	34
139	Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy. BMC Cardiovascular Disorders, 2020, 20, 516.	0.7	33
140	Stress Echo 2030: The Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging. Journal of Clinical Medicine, 2021, 10, 3641.	1.0	33
141	'End-stage' hypertrophic cardiomyopathy: from mystery to model. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 232-233.	3.3	32
142	Early Results of Sarcomeric Gene Screening from the Egyptian National BA-HCM Program. Journal of Cardiovascular Translational Research, 2013, 6, 65-80.	1.1	31
143	Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (Î²-Myosin Heavy) Tj ETQq1 1 0.784314 rgBT / Cardiovascular Imaging, 2017, 10, .	1.3	31
144	Baseline ECG Features and Arrhythmic Profile in Transthyretin Versus Light Chain Cardiac Amyloidosis. Circulation: Heart Failure, 2020, 13, e006619.	1.6	31

#	Article	IF	Citations
145	Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2017, 231, 115-119.	0.8	30
146	External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. European Journal of Preventive Cardiology, 2022, 29, 678-686.	0.8	30
147	Clinical significance of atrial fibrillation in hypertrophic cardiomyopathy. Current Cardiology Reports, 2001, 3, 141-146.	1.3	29
148	Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 866-875.	3.3	29
149	Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team. International Journal of Cardiology, 2020, 304, 86-92.	0.8	29
150	Clinical Profile of Cardiac Involvement in Danon Disease. Circulation Genomic and Precision Medicine, 2020, 13, e003117.	1.6	29
151	A machine learning-based risk stratification model for ventricular tachycardia and heart failure in hypertrophic cardiomyopathy. Computers in Biology and Medicine, 2021, 135, 104648.	3.9	27
152	Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study. Heart Rhythm, 2020, 17, 1107-1114.	0.3	26
153	Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. Journal of Nuclear Cardiology, 2009, 16, 92-96.	1.4	25
154	Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 117, 1151-1159.	0.7	25
155	Cardiac Resynchronization TherapyÂfor End-Stage Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2018, 71, 464-466.	1.2	25
156	Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction. American Heart Journal, 2006, 151, 1094-1100.	1.2	23
157	Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-HeartÂ®). International Journal of Cardiology, 2017, 236, 249-252.	0.8	23
158	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. ESC Heart Failure, 2021, 8, 95-105.	1.4	23
159	Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy. International Journal of Cardiology, 2019, 291, 77-82.	0.8	22
160	Clinical presentation and longâ€term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study. ESC Heart Failure, 2021, 8, 5057-5067.	1.4	22
161	Effects of aging on neuroendocrine activation in subjects and patients in the presence and absence of heart failure with left ventricular systolic dysfunction. American Journal of Cardiology, 1996, 77, 1197-1201.	0.7	21
162	The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: do patients with gradients really deserve prophylactic defibrillators?. European Heart Journal, 2006, 27, 1895-1897.	1.0	21

#	Article	IF	Citations
163	Clinical profile and outcome of cardiac involvement in MELAS syndrome. International Journal of Cardiology, 2019, 276, 14-19.	0.8	21
164	Advantages and Perils of Clinical Whole-Exome and Whole-Genome Sequencing in Cardiomyopathy. Cardiovascular Drugs and Therapy, 2020, 34, 241-253.	1.3	21
165	Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany. International Journal of Cardiology, 2021, 335, 123-127.	0.8	21
166	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization â€" the first insight from the AC-TIVE Study. European Journal of Preventive Cardiology, 2022, 29, e173-e177.	0.8	21
167	Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2413-2422.	3.3	20
168	Atrial Dysfunction Assessed by Cardiac Magnetic Resonance as an Early Marker of Fabry Cardiomyopathy. JACC: Cardiovascular Imaging, 2020, 13, 2262-2264.	2.3	20
169	The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy. European Journal of Preventive Cardiology, 2022, 29, 645-653.	0.8	20
170	Clinical Features and Natural History of Preadolescent Nonsyndromic HypertrophicÂCardiomyopathy. Journal of the American College of Cardiology, 2022, 79, 1986-1997.	1.2	20
171	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churgâ€"Strauss syndrome). European Respiratory Journal, 2021, 57, 2004158.	3.1	19
172	Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives. Current Heart Failure Reports, 2021, 18, 169-179.	1.3	19
173	Molecular Modeling of Disease Causing Mutations in Domain C1 of cMyBP-C. PLoS ONE, 2013, 8, e59206.	1.1	19
174	Early discharge after acute myocardial infarction in the current clinical practice. Community data from the AMI-Florence Registry, Italy. International Journal of Cardiology, 2007, 114, 57-63.	0.8	18
175	Regulation of intracellular Na+in health and disease: pathophysiological mechanisms and implications for treatment. Global Cardiology Science & Practice, 2013, 2013, 30.	0.3	18
176	Grey zones in cardiomyopathies: defining boundaries between genetic and iatrogenic disease. Nature Reviews Cardiology, 2017, 14, 102-112.	6.1	18
177	Emerging Medical Treatment for Hypertrophic Cardiomyopathy. Journal of Clinical Medicine, 2021, 10, 951.	1.0	18
178	Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy. Heart Failure Clinics, 2021, 17, 303-313.	1.0	18
179	Maximal Wall Thickness Measurement in Hypertrophic Cardiomyopathy. JACC: Cardiovascular Imaging, 2021, 14, 2123-2134.	2.3	18
180	Sexâ€Related Differences in Genetic Cardiomyopathies. Journal of the American Heart Association, 2022, 11, e024947.	1.6	18

#	Article	IF	Citations
181	Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter. Journal of the American Heart Association, 2022, 11, e024656.	1.6	18
182	Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside. Drugs, 2022, 82, 889-912.	4.9	18
183	Midventricular Obstruction and Clinical Decision-Making in Obstructive Hypertrophic Cardiomyopathy. Herz, 2006, 31, 871-876.	0.4	17
184	Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy. International Journal of Cardiology, 2018, 273, 155-161.	0.8	17
185	Heritability in genetic heart disease: the role of genetic background. Open Heart, 2019, 6, e000929.	0.9	17
186	Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. Current Cardiology Reports, 2021, 23, 79.	1.3	17
187	Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis. International Journal of Cardiology, 2022, 357, 88-94.	0.8	17
188	Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2010, 140, 1046-1052.	0.4	16
189	Predicting Mortality Risk in Older Hospitalized Persons With COVID-19: A Comparison of the COVID-19 Mortality Risk Score with Frailty and Disability. Journal of the American Medical Directors Association, 2021, 22, 1588-1592.e1.	1.2	16
190	Performance of the CHA2DS2-VASc score in predicting new onset atrial fibrillation during hospitalization for community-acquired pneumonia. European Journal of Internal Medicine, 2019, 62, 24-28.	1.0	15
191	Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy. European Journal of Preventive Cardiology, 2020, 27, 1821-1831.	0.8	15
192	Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2020, 318, 94-100.	0.8	15
193	Prescribing, dosing and titrating exercise in patients with hypertrophic cardiomyopathy for prevention of comorbidities: Ready for prime time. European Journal of Preventive Cardiology, 2021, 28, 1093-1099.	0.8	15
194	Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy. Clinical Cardiology, 2020, 43, 430-440.	0.7	15
195	Predictors of mortality and adverse events in patients with infective endocarditis: a retrospective real world study in a surgical centre. BMC Cardiovascular Disorders, 2021, 21, 28.	0.7	15
196	Clinical and molecular classification of cardiomyopathies. Global Cardiology Science & Practice, 2012, 2012, 4.	0.3	14
197	An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research, 2015, 8, 232-243.	1.1	14
198	Impact of disease-causing mutations on inter-domain interactions in cMyBP-C: a steered molecular dynamics study. Journal of Biomolecular Structure and Dynamics, 2017, 35, 1916-1922.	2.0	14

#	Article	IF	Citations
199	Intraoperative Diagnosis of Anderson-Fabry Disease in Patients With Obstructive Hypertrophic Cardiomyopathy Undergoing Surgical Myectomy. JAMA Cardiology, 2017, 2, 1147.	3.0	14
200	Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: Longâ€term results and clinical outcomes. Journal of Cardiovascular Electrophysiology, 2021, 32, 657-666.	0.8	14
201	Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Medicine, 2021, 85, 68-79.	1.0	14
202	Myocardial bridging and sudden death in hypertrophic cardiomyopathy: Salome drops another veil. European Heart Journal, 2009, 30, 1549-1550.	1.0	13
203	Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy. Global Cardiology Science & Practice, 2012, 2012, 9.	0.3	13
204	Effects of myocardial fibrosis assessed by MRI on dynamic left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: a retrospective database analysis. BMJ Open, 2012, 2, e001267.	0.8	13
205	Chagas disease as a cause of heart failure and ventricular arrhythmias in patients long removed from endemic areas. Journal of Cardiovascular Medicine, 2015, 16, 817-823.	0.6	13
206	The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. Revista Portuguesa De Cardiologia (English Edition), 2018, 37, 1-10.	0.2	13
207	Embolic risk stratification and prognostic impact of early surgery in left-sided infective endocarditis. European Journal of Internal Medicine, 2020, 78, 82-87.	1.0	13
208	Creatine deficiency and heart failure. Heart Failure Reviews, 2022, 27, 1605-1616.	1.7	13
209	Effectiveness of a multidisciplinary chest pain unit for the assessment of coronary syndromes and risk stratification in the Florence area. American Heart Journal, 2002, 144, 630-635.	1.2	12
210	Hypertrophic cardiomyopathy in the community: why we should care. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 324-325.	3.3	12
211	Minimally Invasive and Noninvasive Hemodynamic Monitoring of the Cardiovascular System: Available Options and Future Perspectives. Current Cardiology Reviews, 2006, 2, 37-39.	0.6	12
212	Validation of pixel-wise parametric mapping of myocardial blood flow with 13NH3 PET in patients with hypertrophic cardiomyopathy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1581-1588.	3.3	12
213	Clinical and Laboratory Follow-up After Hospitalization for COVID-19 at an Italian Tertiary Care Center. Open Forum Infectious Diseases, 2021, 8, ofab049.	0.4	12
214	Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy. Heart, 2022, 108, 54-60.	1.2	12
215	Targeted Medical Therapies for Hypertrophic Cardiomyopathy. Current Cardiology Reports, 2020, 22, 10.	1.3	12
216	Sport practice in hypertrophic cardiomyopathy: running to stand still?. International Journal of Cardiology, 2021, 345, 77-82.	0.8	12

#	Article	IF	Citations
217	The Left Ventricular Outflow in Hypertrophic Cardiomyopathy: From Structure to Function. Journal of Cardiovascular Translational Research, 2009, 2, 510-517.	1.1	11
218	Distal extremity pain as a presenting feature of Fabry's disease. Arthritis Care and Research, 2011, 63, 390-395.	1.5	11
219	Response to Letter Regarding Article, â€œLate Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathyâ€. Circulation, 2013, 128, e157.	1.6	11
220	INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on) Tj ETQq0 0 0 rgBT /Overlock 10 T 2015, 2015, 7.	0.3	11
221	Dissecting functional impairment in hypertrophic cardiomyopathy by dynamic assessment of diastolic reserve and outflow obstruction: A combined cardiopulmonary-echocardiographic study. International Journal of Cardiology, 2017, 227, 743-750.	0.8	11
222	Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. Genetics in Medicine, 2021, 23, 1281-1287.	1.1	11
223	Arrhythmogenic potential of myocardial disarray in hypertrophic cardiomyopathy: genetic basis, functional consequences and relation to sudden cardiac death. Europace, 2021, 23, 985-995.	0.7	11
224	Sex-related differences in ventricular remodeling after myocardial infarction. International Journal of Cardiology, 2021, 339, 62-69.	0.8	11
225	Acceptability, Feasibility and Preliminary Evaluation of a Novel, Personalised, Home-Based Physical Activity Intervention for Chronic Heart Failure (Active-at-Home-HF): a Pilot Study. Sports Medicine - Open, 2019, 5, 45.	1.3	11
226	Sex-related differences in clinical presentation and all-cause mortality in patients with cardiac transthyretin amyloidosis and light chain amyloidosis. International Journal of Cardiology, 2022, 351, 71-77.	0.8	11
227	Tunneled left anterior descending artery in a child with hypertrophic cardiomyopathy. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 134-139.	3.3	10
228	Hypertrophic cardiomyopathy: The need for randomized trials. Global Cardiology Science & Practice, 2013, 2013, 31.	0.3	10
229	Electromechanical dissociation of left atrium in patients with Cardiac Amyloidosis by Magnetic Resonance: Prognostic and clinical correlates. IJC Heart and Vasculature, 2020, 31, 100633.	0.6	10
230	A computational pipeline for data augmentation towards the improvement of disease classification and risk stratification models: A case study in two clinical domains. Computers in Biology and Medicine, 2021, 134, 104520.	3.9	10
231	Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 2185-2191.	1.4	10
232	Gender Related Differences in the Clinical Presentation of Hypertrophic Cardiomyopathyâ€”An Analysis from the SILICOFCM Database. Medicina (Lithuania), 2022, 58, 314.	0.8	10
233	Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?. Global Cardiology Science & Practice, 2015, 2015, 16.	0.3	9
234	Coronary microvascular function is impaired in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. European Journal of Neurology, 2020, 28, 3809-3813.	1.7	9

#	Article	IF	Citations
235	Advances in Stem Cell Modeling of Dystrophin-Associated Disease: Implications for the Wider World of Dilated Cardiomyopathy. Frontiers in Physiology, 2020, 11, 368.	1.3	9
236	Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 211-212.	1.4	9
237	Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2021, 10, e021141.	1.6	9
238	Impact of cardiovascular involvement on the clinical course of paediatric mitochondrial disorders. Orphanet Journal of Rare Diseases, 2020, 15, 196.	1.2	8
239	Antiarrhythmic efficacy of anakinra in a young patient with autoimmune lymphocytic myocarditis. Rheumatology, 2020, 59, e88-e90.	0.9	8
240	Use of Smartphone-operated ECG for home ECG surveillance in COVID-19 patients. European Heart Journal Digital Health, 2021, 2, 175-178.	0.7	8
241	Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis. Journal of Cardiac Failure, 2022, 28, 950-959.	0.7	8
242	Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010075.	2.1	8
243	Syncope and ventricular arrhythmias in hypertrophic cardiomyopathy are not related to the derangement of coronary microvascular function. European Heart Journal, 1997, 18, 1946-1950.	1.0	7
244	Looking for Hypertrophic Cardiomyopathy in the Community: Why Is It Important?. Journal of Cardiovascular Translational Research, 2009, 2, 392-397.	1.1	7
245	Channelopathies, cardiac hypertrophy, and the theory of light. European Heart Journal, 2018, 39, 2908-2910.	1.0	7
246	Is heart failure with preserved ejection fraction a â€˜dementiaâ€™ of the heart?. Heart Failure Reviews, 2022, 27, 587-594.	1.7	7
247	On the Cardiac Loop and Its Failing: Left Ventricular Outflow Tract Obstruction. Journal of the American Heart Association, 2020, 9, e014857.	1.6	7
248	Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanisms and clinical consequences. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2004, 5, 572-80.	0.1	7
249	Implantable cardioverter-defibrillators for hypertrophic cardiomyopathy: The Times They Are a-Changinâ€™. Europace, 2021, , .	0.7	7
250	Generation of virtual patient data for in-silico cardiomyopathies drug development using tree ensembles: a comparative study. , 2020, 2020, 5343-5346.		6
251	Prognostic Value of Reduced Heart Rate Reserve during Exercise in Hypertrophic Cardiomyopathy. Journal of Clinical Medicine, 2021, 10, 1347.	1.0	6
252	Neither Athletic Training nor Detraining Affects LV Hypertrophy in Adult, Low-RiskÂPatients With HCM. JACC: Cardiovascular Imaging, 2022, 15, 170-171.	2.3	6

#	Article	IF	Citations
253	Prevalence of Inherited Cardiac Diseases Among Young Patients Requiring Permanent Pacing. Circulation: Arrhythmia and Electrophysiology, 2021, 14, CIRCEP121010562.	2.1	6
254	Impact of SARSâ€Covâ€2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. ESC Heart Failure, 2022, 9, 2189-2198.	1.4	6
255	New Concepts in Hypertrophic Cardiomyopathies. Circulation, 2002, 105, e188; author reply e188.	1.6	5
256	Ventricular tachyarrhythmias and sudden cardiac death in lightâ€chain amyloidosis: a clash of cardioâ€toxicities?. British Journal of Haematology, 2021, 193, e27-e31.	1.2	5
257	Mavacamten â€" a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy. Kardiologia Polska, 2021, 79, 949-954.	0.3	5
258	Myocardial blood flow in patients with hypertrophic cardiomyopathy receiving perindopril (CARAPaCE): a pilot study. Journal of Cardiovascular Medicine, 2021, 22, 511-513.	0.6	5
259	Disease Progression of Hypertrophic Cardiomyopathy: Modeling Using Machine Learning. JMIR Medical Informatics, 2022, 10, e30483.	1.3	5
260	Genotype-Driven Pathogenesis of Atrial Fibrillation in Hypertrophic Cardiomyopathy: The Case of Different TNNT2 Mutations. Frontiers in Physiology, 2022, 13, 864547.	1.3	5
261	Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond. European Journal of Internal Medicine, 2022, 102, 1-7.	1.0	5
262	Exercise-induced pulmonary hypertension in hypertrophic cardiomyopathy: a combined cardiopulmonary exercise testâ€"echocardiographic study. International Journal of Cardiovascular Imaging, 2022, 38, 2345-2352.	0.2	5
263	Determinants of discrepancies between two-dimensional echocardiographic methods for assessment of maximal left atrial volume. European Heart Journal Cardiovascular Imaging, 2017, 18, 584-602.	0.5	4
264	Common presentation of rare cardiac diseases: Arrhythmias. International Journal of Cardiology, 2018, 257, 351-357.	0.8	4
265	Response by Ho et al to Letter Regarding Article, â€œGenotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)â€. Circulation, 2019, 139, 1559-1560.	1.6	4
266	No heart is an island: hypertrophic cardiomyopathy, diabetes, and the test of time. European Heart Journal, 2019, 40, 1678-1680.	1.0	4
267	IN VIVO OBSERVATION OF RETINAL VASCULAR DEPOSITS USING ADAPTIVE OPTICS IMAGING IN FABRY DISEASE. Retina, 2020, 40, 1623-1629.	1.0	4
268	Mitochondrial Energetics and Ca2+-Activated ATPase in Obstructive Hypertrophic Cardiomyopathy. Journal of Clinical Medicine, 2020, 9, 1799.	1.0	4
269	The Importance of Sex Differences in Patients With Hypertrophic Cardiomyopathy â€" Tailoring Management and Future Perspectives. American Journal of the Medical Sciences, 2020, 360, 433-434.	0.4	4
270	Cardiogenic Shock in Obstructive Hypertrophic Cardiomyopathy Plus Apical Ballooning. JACC: Case Reports, 2021, 3, 433-437.	0.3	4

#	Article	IF	Citations
271	Feasibility of a Combined Mobile-Health Electrocardiographic and Rapid Diagnostic Test Screening for Chagas-Related Cardiac Alterations. Microorganisms, 2021, 9, 1889.	1.6	4
272	Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument. PharmacoEconomics - Open, 2022, 6, 563-574.	0.9	4
273	Left Ventricular Apex Involvement in Hypertrophic Cardiomyopathy. Echocardiography, 2015, 32, 1575-1580.	0.3	3
274	Clinical and Molecular Aspects of Cardiomyopathies. Heart Failure Clinics, 2018, 14, 161-178.	1.0	3
275	Genetic testing in pediatric cardiomyopathies: Implications for diagnosis and management. Progress in Pediatric Cardiology, 2018, 51, 24-30.	0.2	3
276	Letter regarding the article â€˜Heart failure with preserved ejection fraction: from mechanisms to therapiesâ€™ by Lam and colleagues. European Heart Journal, 2019, 40, 703-704.	1.0	3
277	Potential resistance to SARS-CoV-2 infection in lysosomal storage disorders. CKJ: Clinical Kidney Journal, 2021, 14, 1488-1490.	1.4	3
278	Endocarditis with spondylodiscitis: clinical characteristics and prognosis. BMC Cardiovascular Disorders, 2021, 21, 186.	0.7	3
279	Recognition of pre-hypertrophic cardiac involvement in Fabry Disease based on automated electrocardiographic measures. International Journal of Cardiology, 2021, 338, 121-126.	0.8	3
280	The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review. Journal of Clinical Medicine, 2021, 10, 416.	1.0	3
281	Epidemiology of cardiomyopathies: essential context knowledge for a tailored clinical work-up. European Journal of Preventive Cardiology, 2020, , .	0.8	3
282	Evaluation of stress myocardial blood flow patterns in patients with apical hypertrophic cardiomyopathy. Journal of Nuclear Cardiology, 2022, 29, 1946-1951.	1.4	3
283	Metabolomics Fingerprint Predicts Risk of Death in Dilated Cardiomyopathy and Heart Failure. Frontiers in Cardiovascular Medicine, 2022, 9, 851905.	1.1	3
284	Variational Gaussian Mixture Models with robust Dirichlet concentration priors for virtual population generation in hypertrophic cardiomyopathy: a comparison study. , 2021, 2021, 1674-1677.		3
285	Sudden death in young athletes: Is it preventable?. European Journal of Internal Medicine, 2022, 104, 13-20.	1.0	3
286	ECG-based screening: not only for athletes. European Heart Journal, 2007, 28, 1170-1170.	1.0	2
287	Incremental prognostic value of multiparametric echocardiographic assessment for severe aortic stenosis. International Journal of Cardiology, 2014, 172, e356-e358.	0.8	2
288	Abrupt Onset of Refractory Heart Failure Associated With Light-Chain Amyloidosis in Hypertrophic Cardiomyopathy. JAMA Cardiology, 2017, 2, 94.	3.0	2

#	Article	IF	Citations
289	Contractile persistence in apical hypertrophic cardiomyopathy: Definitely too much of a good thing. International Journal of Cardiology, 2018, 251, 71-73.	0.8	2
290	A rare case of pediatric cardiomyopathy: AlstrÃ¶m syndrome identified by gene panel analysis. Clinical Case Reports (discontinued), 2020, 8, 3369-3373.	0.2	2
291	The eighth alternative to evidence based medicine in the early era of the COVID-19 pandemic: Too much emergency and emotion, too little evidence. European Journal of Internal Medicine, 2020, 77, 163-164.	1.0	2
292	The labyrinth of nomenclature in Cardiology. Eternal dilemmas and new challenges on the horizon in the personalized medicine era. European Journal of Heart Failure, 2021, 23, 1062-1067.	2.9	2
293	Mavacamten for hypertrophic obstructive cardiomyopathy â€“ Authors' reply. Lancet, The, 2021, 397, 369-370.	6.3	2
294	1â€...The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy. , 2021, , .		2
295	Age-dependent diagnostic yield of echocardiography as a second-line diagnostic investigation in athletes with abnormalities at preparticipation screening. Journal of Cardiovascular Medicine, 2021, 22, 759-766.	0.6	2
296	Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy. Clinical and Translational Medicine, 2021, 11, e435.	1.7	2
297	Feasibility and outcome of mitral valve repair in patients with infective endocarditis. The Cardiothoracic Surgeon, 2020, 28, .	0.2	2
298	Sudden cardiac death in cardiomyopathies: acting upon â€œacceptableâ€•risk in the personalized medicine era. Heart Failure Reviews, 2022, 27, 1749-1759.	1.7	2
299	Strength of clinical indication and therapeutic impact of the implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2022, 353, 62-67.	0.8	2
300	The epidemiologic evolution and present perception of hypertrophic cardiomyopathy. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2003, 4, 596-601.	0.1	2
301	Sex related differences in exercise performance in patients with hypertrophic cardiomyopathy: Hemodynamic insights through non-invasive pressure volume analysis. International Journal of Cardiology, 2022, 351, 78-83.	0.8	2
302	Response to Letter Regarding Article, â€œHypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstructionâ€• Circulation, 2007, 115, .	1.6	1
303	Hypertrophic Cardiomyopathy in Anderson-Fabry Disease. Clinical Therapeutics, 2007, 29, S93-S94.	1.1	1
304	Reply. Journal of the American College of Cardiology, 2014, 64, 2562.	1.2	1
305	Electrophysiological correlates of word recognition memory process in patients with ischemic left ventricular dysfunction. Clinical Neurophysiology, 2016, 127, 3007-3013.	0.7	1
306	Cardiomyopathies in children â€“ inherited heart muscle disease. Progress in Pediatric Cardiology, 2018, 51, 8-15.	0.2	1

#	Article	IF	Citations
307	Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitude. American Heart Journal, 2019, 214, 28-35.	1.2	1
308	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 30-month results from the randomized phase 3 ATTRACT study. Molecular Genetics and Metabolism, 2019, 126, S53.	0.5	1
309	121â€...Re-evaluating the genetic contribution of monogenic dilated cardiomyopathy. , 2019, , .		1
310	Exercise testing in hypertrophic cardiomyopathy: A pathophysiological goldmine with protean clinical implications. International Journal of Cardiology, 2019, 274, 257-259.	0.8	1
311	Doctor-patient care relationship in genetic cardiomyopathies: An exploratory study on clinical consultations. PLoS ONE, 2020, 15, e0236814.	1.1	1
312	Anti-arrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: The importance of optimal beta-blocker dose titration. International Journal of Cardiology, 2021, 338, 150-151.	0.8	1
313	Microvascular ischaemia after cardiac arrest in a patient with hypertrophic cardiomyopathy. Global Cardiology Science & Practice, 2015, 2015, 51.	0.3	1
314	The coronary microcirculation in sepsis: not of micro-importance. Global Cardiology Science & Practice, 2020, 2020, e202030.	0.3	1
315	The Influence of Genotype on the Phenotype, Clinical Course, and Risk of Adverse Events in Children with Hypertrophic Cardiomyopathy. Heart Failure Clinics, 2021, 18, 1-8.	1.0	1
316	PARADOXICAL PROLONGATION OF QT INTERVAL DURING EXERCISE IN PATIENTS WITH HCM: CELLULAR MECHANISMS AND IMPLICATIONS FOR DIASTOLIC FUNCTION. European Heart Journal Open, 0, , .	0.9	1
317	Bayesian Inference-Based Gaussian Mixture Models With Optimal Components Estimation Towards Large-Scale Synthetic Data Generation for In Silico Clinical Trials. IEEE Open Journal of Engineering in Medicine and Biology, 2022, 3, 108-114.	1.7	1
318	Hypertrophic Cardiomyopathy at 50. Journal of Cardiovascular Translational Research, 2009, 2, 339-340.	1.1	0
319	Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	1.6	0
320	Genetic testing for hypertrophic cardiomyopathy: ongoing voyage from exploration to clinical exploitation. Neurology International, 2011, 1, 3.	0.2	0
321	Determinants of Abnormal Excitation-Contraction Coupling in Cardiomyocytes from Patients with Hypertrophic Cardiomyopathy. Biophysical Journal, 2013, 104, 106a.	0.2	0
322	Beta-Adrenergic Response in Human HCM Myocardium: Effects of Ranolazine. Biophysical Journal, 2014, 106, 347a.	0.2	0
323	Reversible Dilated Cardiomyopathy: Into the Thaumaturgy of the Heartâ€"Part 1. Neurology International, 2016, 6, 5861.	0.2	0
324	Reversible dilated cardiomyopathy: into the thaumaturgy of the heart - Part 2. Neurology International, 2016, 6, .	0.2	0

#	Article	IF	Citations
325	Can anthropology improve our care of inherited cardiac arrhythmias? A modest proposal. Heart Rhythm, 2016, 13, 2395-2398.	0.3	0
326	Atrial Remodeling in Hypertrophic Cardiomyopathy. Biophysical Journal, 2017, 112, 556a.	0.2	0
327	Reply to: Is subcutaneous implantable cardioverter-defibrillator testing effective and safe for patients with hypertrophic cardiomyopathy?. International Journal of Cardiology, 2017, 246, 55.	0.8	0
328	The Missense E258K-MyBP-C Mutation Increases the Energy Cost of Tension Generation in Both Ventricular and Atrial Tissue from HCM Patients. Biophysical Journal, 2018, 114, 314a.	0.2	0
329	Rare X-linked storage heart diseases are tougher on men but not kind to women. International Journal of Cardiology, 2019, 286, 113-114.	0.8	0
330	CORRELATION OF ECHOCARDIOGRAPHIC FINDINGS WITH SYMPTOMS IN HYPERTROPHIC CARDIOMYOPATHY PATIENTS. Journal of the American College of Cardiology, 2019, 73, 990.	1.2	0
331	Comment on: Assessment of cardiac disease in MELAS requires comprehensive, prospective work-up. International Journal of Cardiology, 2019, 280, 162.	0.8	0
332	Stress Echocardiography in Hypertrophic Cardiomyopathy. , 2015, , 551-568.		0
333	Abstract 16333: Racial Differences in Pressure-volume Relationships in Val122Ile Associated Cardiac Amyloidosis. Circulation, 2020, 142, .	1.6	0
334	Abstract 15391: The Natural History of Asymptomatic and Mildly Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the Share Registry. Circulation, 2020, 142, .	1.6	0
335	Abstract 14117: Clinical Characteristics and Cardiovascular Outcomes in Childhood-Onset Hypertrophic Cardiomyopathy. Circulation, 2020, 142, .	1.6	0
336	The Inglorious Art. JAMA Cardiology, 2022, 7, 127.	3.0	0
337	465â€ƒUnmasking the prevalence of cardiac amyloidosis in the real world: first insights from the phase 2 of active study, an Italian nationwide survey. European Heart Journal Supplements, 2021, 23, .	0.0	0